JUNO Insider Trading Activity and SEC Form 4 Filings
JUNO insider trading summary
No open-market insider purchases or sales of Juno Therapeutics, Inc. (JUNO) have been reported on SEC Form 4 in the past 12 months.
Latest JUNO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 12, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sell | $356K (4,157 @ $85.55) |
| Feb 8, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sell | $300K (3,497 @ $85.77) |
| Feb 1, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sell | $357K (4,167 @ $85.78) |
| Jan 22, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sell | $8.8M (102,539 @ $86.25) |
| Jan 17, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sell | $559K (7,990 @ $69.95) |
| Jan 17, 2018 | Robert Azelby | EVP & Chief Commercial Officer | Sell | $1.4M (21,141 @ $68.10) |
| Jan 16, 2018 | Hans Edgar Bishop | CEO & President | Sell | $1.1M (23,003 @ $47.69) |
| Jan 16, 2018 | Hans Edgar Bishop | CEO & President | Sell | $2.1M (42,457 @ $48.56) |
| Jan 16, 2018 | Hans Edgar Bishop | CEO & President | Sell | $2.9M (65,820 @ $44.72) |
| Jan 16, 2018 | Hans Edgar Bishop | CEO & President | Sell | $4.1M (89,888 @ $45.53) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.